Whats new

Whats new.

Maxim - P1 Study of IMP761 Moves to Dose Escalation Portion of Trial; Watching for Updates Around Three Core Efti Programs; Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

October 21st 2024

For a copy of this analyst report please contact your Maxim advisor

Go back